Myotonic dystrophy
RSS feedClassical form of Steinert’s disease: 3 possible different cognitive profiles
Cognitive impairment may occur in the adult-onset form of Steinert disease. This can vary greatly from one person to another. A study from Lille characterised cognitive impairment in 124 adult patients aged between 19 and 73: Their work revealed three types of cognitive profile, which seemed to be influenced by age and the time elapsed … [Read more]
AOC 1001 in DM1: positive data after one year of treatment in the MARINA trial
The MARINA trial is a double-blind, placebo-controlled Phase I/II trial which evaluated AOC 1001 for six months in Steinert’s disease (or DM1). It was followed by an open-label extension, the results of which were announced at the Muscular Dystrophy Association congress in March 2024. After one year of treatment, they confirm the preliminary results previously … [Read more]
Overview of neuromuscular diseases
After a brief reminder of the structure of the motor unit and the various modes of inheritance, this document provides short descriptions of the neuromuscular diseases that are part of our scope at AFM-Téléthon, as well as how to manage and treat them. For each group of diseases, as well as in the motor unit … [Read more]
Sleep disordered breathing in slowly progressive myopathies: beyond alveolar hypoventilation
A French retrospective study of the records of 149 adults with an average age of 46.5 years and suffering from myotonic dystrophy (45) , myasthenia (20), Pompe disease (9), spinal muscular atrophy (8), facioscapulohumeral myopathy (8), Duchenne myopathy (5), Becker myopathy (1) or another neuromuscular disease (53) explored by respiratory polygraphy, nocturnal transcutaneous capnography and … [Read more]
Results of phase II trial testing erythromycin in DM1
Based on its efficacy in a mouse model of Steinert’s disease (DM1), a Japanese team evaluated erythromycin (MYD-0124) against placebo in 30 DM1 patients treated for six months. The treatment was well tolerated. Two out of eleven biomarkers (splicing abnormalities of the MBNL1 and CACNA1 genes) were improved in the treated group compared with the … [Read more]
DYNE-101 trial in Steinert disease: preliminary results announced
Dyne Therapeutics, the company developing the antisense oligonucleotide DYNE-101 for Steinert disease, has published initial results from its ongoing ACHIEVE trial. This is a Phase I/II trial starting with a dose escalation phase. The treatment appears to be well tolerated at all three doses tested. Improvements in myotonia and in the Myotonic Dystrophy Health Index … [Read more]
Compliance with non-invasive ventilation is not related to respiratory parameters in DM1
Dutch researchers studied compliance with non-invasive mechanical ventilation (NIV) prescribed as part of respiratory management for patients with Steinert’s disease (DM1). 101 patients who had been prescribed this equipment were monitored for at least one year, at the end of the year, 58 of them showed little or no compliance, these results being in line … [Read more]
Results of the phase II-III trial of AMO-02 in congenital DM1
The results of the international REACH-CDM trial involving 56 children aged between 6 and 16 with the congenital form of myotonic dystrophy type 1 were announced in a press release on 6 September 2023. The primary endpoint, the Clinician-Completed Congenital DM1 Rating Scale, was not met. A significant reduction in CPK enzymes was measured in … [Read more]
Senolytic molecules improve the behaviour of muscle stem cells in DM1
In DM1, muscle stem cells adopt the characteristics of senescent cells, including the secretion of senescence-associated secretory phenotype (SASP). A Canadian team showed that : serum levels of certain SASPs (including interleukin 6) are correlated with muscle weakness and functional limitations. administration of a senolytic product inhibiting BCL-XL leads to the death of senescent myoblasts … [Read more]
A simple algorithm for predicting respiratory impairment in myotonic dystrophies
German researchers have developed a method to better detect ventilatory disorders in patients with DM1 or DM2 myotonic dystrophy. The method is based on a checklist known as “Respicheck”, which takes into account several clinical parameters coupled with functional respiratory tests: 172 people took part in a complementary study to validate Respicheck, 74 had DM1, … [Read more]
